Gilead Sciences Inc (GILD)
Net profit margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Net income | US$ in thousands | 480,000 | 5,665,000 | 4,592,000 | 6,225,000 | 89,000 |
Revenue | US$ in thousands | 28,754,000 | 27,116,000 | 27,281,000 | 27,305,000 | 24,689,000 |
Net profit margin | 1.67% | 20.89% | 16.83% | 22.80% | 0.36% |
December 31, 2024 calculation
Net profit margin = Net income ÷ Revenue
= $480,000K ÷ $28,754,000K
= 1.67%
The net profit margin of Gilead Sciences Inc has displayed significant fluctuations over the years, ranging from a low of 0.36% on December 31, 2020, to a peak of 22.80% on December 31, 2021. This indicates a notable improvement in profitability from 2020 to 2021. However, there was a decrease in net profit margin to 16.83% in 2022, followed by a recovery to 20.89% in 2023. The margin then dropped notably to 1.67% by December 31, 2024. These fluctuations suggest varying levels of efficiency in generating profits relative to revenue during the specified periods.
Peer comparison
Dec 31, 2024
Company name
Symbol
Net profit margin
Gilead Sciences Inc
GILD
1.67%
ADMA Biologics Inc
ADMA
46.35%
Amgen Inc
AMGN
12.24%
Bio-Techne Corp
TECH
14.50%
Biogen Inc
BIIB
16.87%
Halozyme Therapeutics Inc
HALO
43.74%
Krystal Biotech Inc
KRYS
30.06%
Moderna Inc
MRNA
-110.04%
Neurocrine Biosciences Inc
NBIX
14.49%
Repligen Corporation
RGEN
-4.02%
Vericel Corp Ord
VCEL
4.37%